MyChesCo on MSN

ENHERTU Shows Strong Results in Early Breast Cancer Trial

AstraZeneca and Daiichi Sankyo reported that their drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved highly ...
BioPharma Dive

Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
Medical Herald

AstraZeneca and Daiichi Sankyo Achieve Milestone in Cancer Study

AstraZeneca and Daiichi Sankyo’s Datroway shows strong results in a late-stage trial for triple-negative breast cancer, ...

Schroder Japan Trust performance weakens on-year but beats benchmark

NAV total return for the year that ended July 31 fell to 6.8% from 21.0% in financial 2024. Nonetheless, Schroder Japan beat its benchmark, the Tokyo Stock Price index, whose total return was 4.8%.
Asianet Newsable on MSN

Fortis Rally Backed By IHH Stake Buy; SEBI Analyst Sees Healthy Says ‘Multibagger’ Setup Emerging

Shares of Fortis Healthcare rose over 1% on Wednesday on the heels of SEBI’s approval for IHH Healthcare’s plan to buy an ...
FMIBlog

Hemorrhagic Stroke Treatment Market Poised to Reach USD 6.8 Billion by 2035, Driven by Expanding Healthcare Infrastructure

The global Hemorrhagic Stroke Treatment Market is on the path to significant growth, projected to increase from USD 3.7 ...
Pharmabiz

Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer

Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer: Tokyo Wednesday, October 8, ...